Compare SPWH & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPWH | ENTX |
|---|---|---|
| Founded | 1986 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 47.2M |
| IPO Year | 2014 | 2015 |
| Metric | SPWH | ENTX |
|---|---|---|
| Price | $1.31 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $2.95 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 402.1K | 164.0K |
| Earning Date | 03-31-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $1,197,633,000.00 | $42,000.00 |
| Revenue This Year | $2.95 | N/A |
| Revenue Next Year | $0.08 | N/A |
| P/E Ratio | ★ N/A | $6.28 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $0.98 |
| 52 Week High | $4.33 | $3.22 |
| Indicator | SPWH | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 38.24 |
| Support Level | $1.27 | N/A |
| Resistance Level | $1.50 | $1.61 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 43.75 | 13.64 |
Sportsman's Warehouse Holdings Inc together with its subsidiaries operates as an outdoor sporting goods retailer. It provides a one-stop shopping experience that equips customers with the right quality, brand name hunting, shooting, fishing, and camping gear to maximize enjoyment of the outdoors. The company offers products in the categories of Camping, Apparel, Fishing, Footwear, Hunting and shooting, and Optics, Electronics, Accessories, and Other products. It provides products such as Backpacks, Jackets, Camp essentials, Hiking boots, GPS devices, ATV accessories and Fishing rods, among others.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.